Top in rheumatology: Prior authorization; CAR-T cell therapy for lupus
CMS recently announced new proposals to streamline the prior authorization process.
Michael Putman, MD, MSci, of the Medical College of Wisconsin, told Healio that the overall effects of these proposed changes will likely be minimal.
“Prior authorizations are not going away and will continue to consume valuable time and resources that could be spent elsewhere,” he said.
It was the top story in rheumatology last week.
Another top story was about a small study that suggests chimeric antigen receptor T-cell therapy may benefit patients with systemic lupus erythematosus.
Read these and more top stories in rheumatology below:
CMS proposes rule to streamline prior authorization, require justification for denials
CMS has proposed new rules intended to improve access to health information and “streamline” processes that are involved with prior authorization, according to a press release from the agency. Read more.
‘Huge surprise’: CAR-T cell therapy leads to remission in severe lupus
Five patients with systemic lupus erythematosus achieved remission after receiving chimeric antigen receptor T-cell therapy, a result that could change the face of treatment for autoimmune conditions, according to researchers. Read more.
Patients with chronic sleep deprivation at higher risk for lupus
Individuals with chronic sleep deprivation demonstrate a higher risk for developing systemic lupus erythematosus, with stronger effects in those with depression and bodily pain, according to data published in Arthritis Care & Research. Read more.
Dementia more common in patients with RA receiving csDMARDs vs b/tsDMARDs
Dementia is more common in patients with rheumatoid arthritis who receive conventional synthetic disease modifying anti-rheumatic drugs vs. biologics or targeted synthetic treatments, according to data. Read more.
Patients with AS who start TNF inhibition early have higher cardiovascular risk
Patients who started TNF inhibitors earlier in their ankylosing spondyloarthritis disease course, vs. no initiation, have a higher risk for cardiovascular events, according to data presented at ACR Convergence 2022. Read more.